Filtered By:
Source: Thrombosis and Haemostasis
Condition: Bleeding
This page shows you your search results in order of relevance. This is page number 11.
Order by Relevance | Date
Total 164 results found since Jan 2013.
State-of-the-art-mini review: Dual pathway inhibition to reduce arterial and venous thromboembolism
Thromb Haemost. 2022 Feb 21. doi: 10.1055/a-1778-1083. Online ahead of print.ABSTRACTVenous thromboembolism (VTE) and arterial thromboembolism (ATE) are linked by the common mechanism of thrombin generation. Historically these entities have been treated as separate pathophysiologic processes requiring different treatments: VTE, as the formation of fibrin-/coagulation-factor-derived thrombus in low flow vasculature, requiring anticoagulants; versus ATE, as largely platelet-derived thrombus in high flow vasculature, requiring antiplatelet agents. Observational studies have elucidated shared risk factors and co-morbidities pr...
Source: Thrombosis and Haemostasis - February 21, 2022 Category: Hematology Authors: Mark Goldin Ioannis Koulas Jeffrey I Weitz Alex Spyropoulos Source Type: research
Rivaroxaban Underdose for Atrial Fibrillation with Stable Coronary Disease: The AFIRE Trial Findings
CONCLUSION: In patients with AF, stable CAD, and preserved renal function, rivaroxaban underdose was associated with similar rates of thrombotic events but a lower incidence of hemorrhagic events than the standard dose.CLINICAL TRIAL REGISTRATION: AFIRE UMIN Clinical Trials Registry (https://www.umin.ac.jp/ctr/), number UMIN000016612, and ClinicalTrials.gov, number NCT02642419.PMID:35697255 | DOI:10.1055/s-0042-1744543
Source: Thrombosis and Haemostasis - June 13, 2022 Category: Hematology Authors: Hiroyuki Arashi Junichi Yamaguchi Nobuhisa Hagiwara Satoshi Yasuda Koichi Kaikita Masaharu Akao Junya Ako Tetsuya Matoba Masato Nakamura Katsumi Miyauchi Kazuo Kimura Atsushi Hirayama Kunihiko Matsui Hisao Ogawa Source Type: research
Clinical Complexity Domains, Anticoagulation, and Outcomes in Patients with Atrial Fibrillation: A Report from the GLORIA-AF Registry Phase II and III
CONCLUSION: In AF patients, clinical complexity influences OAC treatment management, and increases the risk of poor clinical outcomes. These patients require additional efforts, such as integrated care approach, to improve their management and prognosis.PMID:36037828 | DOI:10.1055/s-0042-1756355
Source: Thrombosis and Haemostasis - August 29, 2022 Category: Hematology Authors: Giulio Francesco Romiti Marco Proietti Niccol ò Bonini Wern Yew Ding Giuseppe Boriani Menno V Huisman Gregory Y H Lip GLORIA-AF Investigators Source Type: research
Association between Platelet Count and Treatment Effect of Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
CONCLUSIONS: In this analysis, incidence of ischemic and bleeding events at 12 months are comparable across quartiles of platelet count.PMID:36442805 | DOI:10.1055/a-1988-5047
Source: Thrombosis and Haemostasis - November 28, 2022 Category: Hematology Authors: Tobias Koch Shqipdona Lahu J J Coughlan Salvatore Cassese Felix Voll Gjin Ndrepepa Maurizio Menichelli Christian M Valina Rayyan Hemetsberger Bernhard Witzenbichler Isabell Bernlochner Michael Joner Erion Xhepa Katharina Mayer Thorsten Kessler Karl-Ludwig Source Type: research
Post-PCI Risk Assessment by Inflammation Activity According to Disease Acuity and Time from Procedure
CONCLUSION: AMI patients have greater inflammation during the early and late phases than non-AMI patients. Risk phenotype of hsCRPbaseline correlates with 1-month outcomes only in AMI patients. Whereas the prognostic implication of this risk phenotype appears similar during the late phase, irrespective of the disease acuity.PMID:36634702 | DOI:10.1055/a-2011-8426
Source: Thrombosis and Haemostasis - January 12, 2023 Category: Hematology Authors: Haegeun Song Jong-Hwa Ahn Min Gyu Kang Kye Hwan Kim Jae Seok Bae Sang-Yeong Cho Jin Sin Koh Yongwhi Park Seok-Jae Hwang Eun Jeong Cho Kyeongmin Byeon Sang-Wook Kim Udaya S Tantry Paul A Gurbel Jin-Yong Hwang Young-Hoon Jeong Source Type: research
Thrombosis and bleeding in patients with COVID-19 requiring extracorporeal membrane oxygenation: a systematic review and meta-analysis
CONCLUSIONS: Circuit thrombosis and major bleeding were the most common thrombotic and bleeding events. The incidence of ICH was significantly higher when ECMO was indicated for COVID-19 than for other respiratory diseases. There is no evidence for stronger anticoagulation practice, and remains no consistent anticoagulation strategy to reduce the occurrence of thrombosis and bleeding under the double "hit" of COVID-19 and ECMO.PMID:36999123 | PMC:PMC9993729 | DOI:10.1016/j.rpth.2023.100103
Source: Thrombosis and Haemostasis - March 31, 2023 Category: Hematology Authors: Yu Jin Yang Zhang Jinping Liu Zhou Zhou Source Type: research
Niemann-Pick C1 protein regulates platelet membrane-associated Ca < sup > 2+ < /sup > signalling in thrombo-occlusive diseases in mice
CONCLUSIONS: Our findings highlight that NPC1 regulates membrane-associated and SERCA3-dependent Ca2+ mobilisation during platelet activation and that MK/platelet-specific ablation of Npc1 protects against experimental models of arterial thrombosis and myocardial or cerebral ischemia/reperfusion injury.PMID:37054918 | DOI:10.1016/j.jtha.2023.03.038
Source: Thrombosis and Haemostasis - April 13, 2023 Category: Hematology Authors: Mailin-Christin Manke Anna Roslan Britta Walker Patrick M ünzer Ferdinand Kollotzek Bing Peng Stine Mencl Cristina Coman Rebecca D Szepanowski Harald Schulze Andrew P Lieberman Florian Lang Meinrad Gawaz Christoph Kleinschnitz Robert Lukowski Robert Ahre Source Type: research
